Similarly, BRAF inhibitors in human A375 sensitive melanomas cells impaired glycolysis in vitro, as attested by a decreased 13C-pyruvate -13C-lactate exchange in response to vemurafenib [34]. This evidence concerns the gene BRAF and melanoma.